Thank you for inviting me to speak to the Public Petitions Committee. It is an honour and a privilege, and I appreciate your giving me 10 minutes to make a statement.
I am a surgeon, not a politician, so I am in unfamiliar territory this afternoon. Many communications have arisen from my interactions with Scotland, and I cannot possibly reference all of them today. However, I believe my account to be fair and accurate.
Mesh-injured women who contemplate undergoing mesh removal surgery do not do so lightly. Surgeries on women following partial mesh removals can be the most difficult gynaecological operations.
Mesh-injured women are in pain and distress, and need transparent medical care. I have successfully removed thousands of mesh implants—slings, prolapse mesh, rectopexy mesh and sacrocolpopexy mesh. For more than 20 years, I have been a surgeon of last resort for women who seek other choices or options, and for women who have had partial removals of mesh by other surgeons and are still in pain. Annually, I perform more than 600 surgeries.
I want to talk about the Scotland offer. When the Scottish Government appointed Terry O’Kelly in June 2019, I worked under the assumption that urgency on the mesh-injured women situation was foremost in everyone’s mind. The goal of the project was to provide surgical help for the mesh-injured women; training local surgeons would be a by-product of helping those women.
On paper, it appeared that everything was in place to make a success of the project. I was assured that Scotland’s medical community wanted to work together, with me, to make the project happen. Team Scotland was backed by the First Minister, the Cabinet Secretary for Health and Sport, the chief medical officer and the assigned lead mesh-removal surgeons, with all the influence and power of those officers. Yet, here we are today. No members of that team have been able to complete the regulatory process and no document has ever been issued that could be considered a letter of intent or an employment contract.
In early November 2019, in St Louis, the then CMO promised me that the regulatory process would be completed within a month of her return. She stated that sponsors had to be obstetrics and gynaecology specialists. Although CMO Calderwood is a consultant obstetrician and gynaecologist and could have endorsed my application, she stated that it would be better if that came from the lead clinician, who was Karen Guerrero. CMO Calderwood assured me that she would provide the necessary sponsorships, letters and employment contract.
In return, and on the condition that the regulatory process be completed, I agreed in principle to visit Scotland in spring 2020, primarily to review patient files, schedule surgery and start the project of caring for the women. There is correspondence that includes the detail of possible itineraries that were discussed, but there was never any agreement that I would visit Scotland before the General Medical Council’s regulatory process had been completed: there was no misunderstanding about that. Only when that crucial step had been completed would I finally have been able to make what I hoped would be the first of multiple extended journeys to Scotland to care for and operate on mesh-injured women.
On returning to Scotland from St Louis, CMO Calderwood shifted the goalposts. She asked me to fly to Scotland in spring 2020 to attend an educational event. That request came one day after I had been contacted by Mr Chris Harding, the mesh spokesman for the British Association of Urological Surgeons, who indicated that he had pitched the idea to CMO Calderwood. She contacted me the next day and stated that it was her idea. When I questioned her as to why she was adding that element to the itinerary, she said that it was about sponsorship and requested that I engage with the attendees and ask for their support to sponsor my GMC application. In short, the Scottish team’s medical members would not be endorsing the GMC application.
I clearly communicated to CMO Calderwood that in no circumstances would I fly to Scotland before completion of the GMC application. The more I communicated that position, the more CMO Calderwood glossed over the problem. She continued to send letters with plans for a visit in spring 2020. I read in the press and in the Scottish Parliament’s official record about my visit in spring 2020. That was barren ground. I was bitterly disappointed for the mesh-injured women, and not only those in Scotland.
What were the problems? There were several indications that there was a great willingness to delay real progress in the project. Phase 1 was June to September 2019. In June 2019, when the project started with Mr O’Kelly, who was appointed by the Cabinet Secretary for Health and Sport, I knew that I would be in Europe for the International Continence Society’s meeting in September. Mr O’Kelly had initially extended to me an invitation to visit Scotland when I was in Europe. However, things changed. He stipulated that the Scottish team must visit me at the Mercy hospital in St Louis. With good grace, I accepted and accommodated a visit that was organised for July, but the team cancelled. The grounds that were given were that Karen Guerrero was not sure of her commitment to the project and had childcare issues during the summer.
I then received an urgent request from Mr O’Kelly to organise a visit in August 2019. I made arrangements once again, but days before the visit the team cancelled due to schedule clashes. When the team cancelled in August 2019, I reminded Mr O’Kelly that I would be in Gothenburg at the ICS conference from 3 to 6 September, and then in the United Kingdom. He suggested that he might visit me and another surgeon in Gothenburg. No further invitation to visit Scotland was extended to me, and since that time I have had no further communication from Mr O’Kelly.
I will mention two issues of note. I was not aware that any Scottish team members would be at the ICS meeting in Gothenburg. During the meeting, a prominent US colleague approached me and stated that the Scottish clinicians at the ICS meeting needed his help in relation to mesh removal, and that he had informed them that I was the best person to help them. That US colleague sent emails introducing me to the Scotland team and attempted to arrange a visit for the team to meet me in St Louis.
In any case, had the team visited me in St Louis in July—or, indeed, in August—I could have visited Scotland in September, when I would be in the UK, and started the process, and I could even have stayed longer, if needed. That made perfect sense to me. However, the surgeons were not on board with the project, despite all the reassurances that I had been given. At that juncture, I withdrew from the project.
In October 2019, I agreed to return to the project following a brief conversation with the First Minister of Scotland. That was at the direction of CMO Calderwood. The Scotland team eventually visited me in early November. I hosted CMO Calderwood, the two lead mesh clinicians, a member of the nursing staff and a member of the physical therapy team. They arrived at my office at 11 am on Thursday 7 November 2019 and departed at 11 am on Friday 8 November. I remain of the opinion that the Scottish team’s 24-hour trip to St Louis was not an essential part of the project.
When CMO Calderwood left St Louis, it was made clear to me that she would ensure that the regulatory process would be completed, as she stated, within a month. When she returned to Scotland, she did a U-turn on that agreement. She made the unreasonable request that the spring 2020 visit would be used as an opportunity for me to canvass and acquire sponsorship from attendees of the educational symposium.
Mr Harding notified me that he was in discussions with CMO Calderwood about the symposium. Again, I do not know what CMO Calderwood communicated to the cabinet secretary, to the First Minister, to her successor interim CMO Gregor Smith, or to Mr Harding. I know the sequence of events that were promised, the first of which was completion of the GMC process.
Any suggestion to the mesh-injured women that I was arriving in spring 2020 was not transparent. First, at no point did I agree to CMO Calderwood’s suggestion that I attend the symposium. I made it clear, in no uncertain terms, that I would not canvass anyone, ever, for sponsorship. Secondly, even if CMO Calderwood had delivered her promise, the purpose of the visit in spring 2020 would not have been to commence any care or surgical treatment for the mesh-injured women. I could have been in Scotland in September 2019.
In conclusion, my involvement in the project is flavoured by delay and what appeared to be a war of attrition. Whatever the motivations, the outcome demonstrated to me that there was no sense of urgency in delivering the project to help the mesh-injured women.
I am happy to answer any questions.